Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durbin/Hatch bill

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Michael Leavitt has promised to examine legislation mandating adverse event reporting for dietary supplements and OTC drugs, Sen. Richard Durbin (D-Ill.), notes during Jan. 26 confirmation hearing. Durbin and Sen. Orrin Hatch (R-Utah) are working together to create an AER bill with input from industry (1"The Tan Sheet" June 28, 2004, p. 3). "There should be a clearinghouse at FDA for manufacturers to provide data about the safety of their products," Durbin says. "As we develop legislation this year, Leavitt has agreed to review it"...

You may also be interested in...



Senators Durbin, Hatch To Work Together On AER Plan

Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Topics

UsernamePublicRestriction

Register

PS097792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel